Ekso Bionics Holdings Inc(EKSO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -5.39 | Insider Own | 24.25% | Shs Outstand | 3.6M | Perf Week | 3.78% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | - | Insider Trans | 9.4% | Shs Float | 2.7M | Perf Month | 25.53% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | - | Inst Own | 22.78% | Short Float | 7.97% | Perf Quarter | 25.93% |
| Income | -0.02B | P/S | 3.64 | EPS this Y | - | Inst Trans | -0.34% | Short Ratio | 2.21 | Perf Half Y | 131.37% |
| Sales | 0.01B | P/B | 20.12 | EPS next 5Y | - | ROA | -68.39% | Short Interest | 0.22M | Perf YTD | 36.57% |
| Book/sh | 0.59 | P/C | 10.54 | EPS past 3/5Y | 34.46% 31.73% | ROE | -217.36% | 52W High | -12.59% ($13.50) | Perf Year | 62.87% |
| Cash/sh | 1.12 | P/FCF | - | Sales past 3/5Y | -0.29% 7.58% | ROIC | -251.76% | 52W Low | 332.23% ($2.73) | Perf 3Y | -49.05% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 26.18% | Gross Margin | 52.86% | Volatility(W/M) | 7.55% 9.31% | Perf 5Y | -85.59% |
| Dividend TTM | - | EV/Sales | 3.98 | Sales Y/Y TTM | -34.08% | Oper. Margin | -134.06% | ATR (14) | 0.92 | Perf 10Y | -99.11% |
| Dividend Ex-Date | - | Quick Ratio | 1.03 | EPS Q/Q | -19.33% | Profit Margin | -138.91% | RSI (14) | 60.21 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.55 | Sales Q/Q | -36.56% | SMA20 | 11.72% ($10.56) | Beta | 0.86 | Target Price | $90 |
| Payout | - | Debt/Eq | 3.81 | Earnings | 2026/02/19 | SMA50 | 10.79% ($10.65) | Rel Volume | 0.99 | Prev Close | $11.79 |
| Employees | 55 | LT Debt/Eq | 2.05 | EPS/Sales Surpr. | 44.04% 1.7% | SMA200 | 72.7% ($6.83) | Avg Volume(3M) | 0.10M | Price | $11.8 |
| IPO | 2014/1/16 | Option/Short | No/Yes | Trades | 1116 | Volume | 96,572 | Change | 0.08% |
A US medical robotics company that builds wearable robotic exoskeletons to aid in the rehabilitation of stroke and spinal cord injury patients. Its flagship product is the EksoNR, and it is evolving into a smart rehabilitation robot equipped with NVIDIA AI voice control capabilities.
Over the past 1 year, on the higher side
13% below its 1-year high.
Traded about as much as usual. That is 99% of its average volume.
EKSO has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $364. Peers typically go for $259.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -85.6%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 22.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
DFAC U.S. Core Equity 2 Portfolio-ETF Class Shares <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #41 of 52 in the industry
Based on market cap of $42M.
POCI#40 Precision Optics Corp Inc $51M PER - EKSO#41 Ekso Bionics Holdings Inc $42M PER - 
DAVI#41 Davion Healthcare Plc $42M PER - 
HBIO#42 Harvard Bioscience Inc $41M PER - 
NEPH#43 Nephros Inc $34M PER 20.3 
FAQ
What kind of company is EKSO?
EKSO belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of EKSO?
The market cap of EKSO is approximately $42M, ranking 5,010 within its sector.
What is the 52-week high and low for EKSO?
EKSO has recorded a 52-week high of $13.50 and a low of $2.73.
